Conclusion
Rituximab is considered an important treatment option in patients with moderate to severe refractory pemphigus vulgaris. RTX has been shown to be effective and well-tolerated in several autoimmune conditions. However, there are still concerns about its long-term adverse effects. Clinicians should be vigilant for potential acute or delayed serum sickness as possible adverse reactions to weigh the risks and benefits of continuing/reintroducing RTX for patients with pemphigus vulgaris. Further studies reporting the adverse effects of RTX are required to establish its safety and tolerability.